Morton Kern, MD, of VA Long Beach Healthcare System and University of California, Irvine, often engages his colleagues via email in brief, informal dialogue on clinically relevant topics in interventional cardiology. With permission from the participants, TCTMD presents their conversations for the benefit of the cardiology community. Your feedback is welcomefeel free to comment at the bottom of the page. Continue reading →

WAYNE, Pa., Nov. Continue reading →

November 8, 2019 Dissection is a frequent and clinically problematic outcome of percutaneous transluminal balloon angioplasty (PTA), and there is no current safe solution for revascularization of below-the-knee (BTK) arteries. The TOBA II BTK Trial looked atusing small stents to tack the vessel if needed without using a full sized stent, which leads to stent fractures BTK. The trial, presented as a late-breaker at the 2019 Vascular Interventional Advances (VIVA) annual meeting, met all endpoints in a 100 percentdissected vessel population Continue reading →

November 8, 2019 The Absorb bioresorbable stent (BVS) demonstrated good patency and clinical outcomes in patients with chronic limb-threatening ischemia (CLTI) in the DISAPEAR Registry. This included complex infrapopliteal disease and comorbidities such as diabetes and renal failure, said Steven Kum, M.D., who presented the trial at the 2019 Vascular Interventional Advances (VIVA) annual meeting. Future prospective controlled studies can further help corroborate the significance of these findings, Kum said Continue reading →

Prespecified Analysis of 3,146 Patients in the USA Enrolled in REDUCE-IT Showed 31% Relative Risk Reductions for First Occurrence of Both 5-Point MACE and 3-Point MACE Significant Reductions Shown in All Predefined Composite and Individual Cardiovascular Endpoints, Including Cardiovascular Death and All-Cause Mortality Tolerability and Safety Findings Consistent with Full Study Results Published Today in Circulation and Scheduled for Presentation at American Heart Association 2019 Scientific Sessions on November 17 DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. Continue reading →

The In-Vitro diagnostic market is valued as a USD 17 billion market in 2013 and is expected to become a USD 25 billion by 2020, growing at a CAGR of 5.66%. Continue reading →

The University of Vermont Health Network has begun a pilot project to offer Genomic DNA Testing to patients as part of their clinical care. The pilot program is the beginning of an effort to increase the integration of genetic disease risks into routine medical care, which holds promise for providing Vermonters with valuable information to guide their health decisions Continue reading →